Fiche publication
Date publication
janvier 2022
Journal
Emerging infectious diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe
,
Pr HERBRECHT Raoul
Tous les auteurs :
Kaeuffer C, Baldacini M, Ruge T, Ruch Y, Zhu YJ, De Cian M, Philouze G, Bachellier P, Denis J, Lefebvre N, Schneider F, Hansmann Y, Letscher-Bru V, Herbrecht R, Sabou M, Danion F
Lien Pubmed
Résumé
Rare fungal pathogens are emerging as agents of invasive fungal infections. We analyzed 13 cases of fungal infections caused by Kazachstania (Arxiozyma) spp. in Strasbourg University Hospital, Strasbourg, France. Among the cases, 4 patients had proven fungal disease (3 cases of invasive fungal disease and 1 mucocutaneous infection) and 9 were colonized by Kazachstania (Arxiozyma) spp. Candida albicans was also isolated from 11 of the 13 patients. None of the patients with proven invasive fungal disease met host criteria, but most had underlying diseases. All strains were identified as K. telluris by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and 3 were confirmed as K. bovina by internal transcribed spacer sequencing. For all tested strains, the MICs for fluconazole were >2 μg/mL. Emergence of this rare fungal infection might be explained by the increasing number of patients with immunocompromised conditions and gastroesophageal diseases.
Mots clés
Candida, France, Kazachstania, emerging infection, fungi, invasive fungal disease, yeast
Référence
Emerg Infect Dis. 2022 Jan;28(1):29-34
